Kazia Therapeutics Limited
KZIA
$6.75
$0.172.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 760.50K | 758.90K | -- |
| Total Other Revenue | 7.30K | 7.50K | 57.00K | 56.90K | 0.00 |
| Total Revenue | 7.30K | 7.50K | 817.50K | 815.80K | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.30K | 7.50K | 817.50K | 815.80K | 0.00 |
| SG&A Expenses | 1.66M | 1.71M | 2.97M | 2.96M | 1.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.06M | 3.15M | 7.27M | 7.25M | 2.89M |
| Operating Income | -3.05M | -3.14M | -6.45M | -6.44M | -2.89M |
| Income Before Tax | -3.45M | -3.55M | -5.96M | -5.95M | -2.92M |
| Income Tax Expenses | -44.20K | -45.40K | -44.60K | -44.50K | -44.20K |
| Earnings from Continuing Operations | -3.41M | -3.50M | -5.92M | -5.90M | -2.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.41M | -3.50M | -5.92M | -5.90M | -2.88M |
| EBIT | -3.05M | -3.14M | -6.45M | -6.44M | -2.89M |
| EBITDA | -2.75M | -2.83M | -6.14M | -6.13M | -2.59M |
| EPS Basic | -2.00K | -2.06K | -5.14K | -5.13K | -3.00K |
| Normalized Basic EPS | -2.72 | -2.79 | -6.58 | -6.57 | -3.73 |
| EPS Diluted | -2.00K | -2.06K | -5.14K | -5.13K | -3.00K |
| Normalized Diluted EPS | -2.72 | -2.79 | -6.58 | -6.57 | -3.73 |
| Average Basic Shares Outstanding | 850.30K | 850.30K | 575.10K | 575.10K | 479.60K |
| Average Diluted Shares Outstanding | 1.70K | 1.70K | 1.10K | 1.10K | 900.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |